Molecular profiling of ctDNA from NCI-MATCH patients enrolled for treatment with mTOR1/2 inhibitor sapanisertib (arm M) and the Hedgehog pathway inhibitor vismodegib (arm T).
Jennifer S. LoCoco(Illumina (United States)), Chris Karlovich(Clovis Oncology (United States)), Lyndsay N. Harris(National Institutes of Health), David R. Patton(National Cancer Institute), Traci Pawlowski(Illumina (United States)), Lisa M. McShane(National Cancer Institute), Amanda Peach(Frederick National Laboratory for Cancer Research), James H. Doroshow(National Cancer Institute), Alice P. Chen(National Institutes of Health), Phillip G. Febbo(Veracyte (United States)), Yao Fu(Illumina (United States)), Sorena Rahmanian(University of California San Diego), Naoko Takebe(National Cancer Institute), P. Mickey Williams(Leidos (United States)), Li Chen(Harvard University), Jessica Li(Universidad San Carlos), Biswajit Das(Frederick National Laboratory for Cancer Research), Robin Harrington(Frederick National Laboratory for Cancer Research), Jennifer L. Silhavy(Howard Hughes Medical Institute), Ting-Chia Chang(Frederick National Laboratory for Cancer Research)
Cited by 2
Related Papers
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0
|Nature Protocols|2011|1.9k
Molecular Definition of Breast Tumor Heterogeneity
|Cancer Cell|2007|1.4k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k